Market Overview

Arrowhead and Shire Enter into Collaboration and License Agreement to Develop Peptide-Targeted Therapeutics

Related ARWR
4 Biotechs Piper Jaffray Is Buying On The Pullback
Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency
Premarket Biotech Digest: Shorts Targeting Biotech, Anavex's Promise, Zarxio Launch (Seeking Alpha)

Arrowhead Research (NASDAQ: ARWR) today announced that it has signed a research collaboration and
license agreement with Shire (OTC: SHPG), to develop and commercialize targeted
peptide-drug conjugates (PDCs) by utilizing Arrowhead's human-derived
Homing Peptide platform and Shire's therapeutic payloads. Arrowhead will
receive research funding and could be eligible for development,
regulatory, and commercialization milestone payments of up to $32.8
million for each development candidate, plus additional milestone
payments for a second indication, and royalties on worldwide sales.
Additional financial terms of the agreement were not disclosed.

“Shire's expertise in developing innovative medicines for rare diseases
makes them an ideal partner for Arrowhead as we advance our platform of

See full press release

Posted-In: News Guidance Financing Contracts Asset Sales Management M&A


Related Articles (ARWR + SHPG)

Get Benzinga's Newsletters